2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: Combining Bismuth-213 with Nanobodies: Finding the Perfect Match for Targeted Alpha Therapy

Ottawa, ON, Canada (UroToday.com) This study is aimed at the use of radio-labeled nanobodies targeting HER2+ tumors such as breast or ovarian cancers. Because of their small size, nanobodies are expected to show good tumor penetration. In vitro studies showed that a Bi213-DPTA-Nb conjugate was stable for several hours and showed high affinity for the HER2+ SKOV-3 cells.

In the second part of the study, two groups of mice were injected with Bi213-DPTA-Nb either with or without 150 mg/kg Gelofusin. Both groups showed good tumor uptake. There is little uptake in normal tissue, but some kidney retention occurred because of excretion through the urine. The kidney retention was reduced by 50% in the Gelofusin arm.


Presented by: Ms. Yana Dekempeneer, Studiecentrum voor Kernenergie (SCK-CEN)

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada